Deverra is a clinical-stage biotechnology company developing universal donor cell therapy treatments to fight cancer and other life-threatening diseases.
Our platform technology uses sustainable, healthy cord blood cells to generate universal cell therapies, meaning no donor-patient matching is needed
Our platform is capable of generating many distinct cell types resulting in a diverse pipeline of cell therapies for multiple indications.
Our scalable manufacturing and effective cryopreservation enables delivery of
We have 20+ years of experience in developing allogeneic off-the-shelf therapies based on federally funded research and across five clinical trials to date
Stem and Progenitor Cell
We provide treatment options for newly diagnosed AML patients with our hematopoietic stem & progenitor cell immunotherapy
Dilanubicel, our lead product, has been evaluated in a global phase 2 randomized controlled trial in patients with newly diagnosed AML. Data from this study demonstrated a statistically significant increase in remission rates in patients who received dilanubicel as an adjuvant to standard of care chemotherapy when compared to patients who received standard of care chemotherapy alone.
Natural Killer Cell
We generate natural killer (NK) cells that are used to fight cancer and to boost immunity against viral infections.
DVX201, our NK cell product, is in clinical trials to treat patients with relapsed/refractory AML or high risk MDS and patients hospitalized with COVID-19. Our goal is to create a family of NK cell therapies that also include NK cells engineered to target specific cancers (CAR-NKs).
We aim to target solid tumors using the patient’s own immune system activated by our myeloid cell product
Our goal is to develop engineered monocyte/macrophage therapies to treat patients with solid tumors, alone or in combination with other cell therapy products generated off our platform.